Business
Cue Biopharma Announces Publication in The Journal of Clinical Investigation Highlighting Immuno-STAT Biologics for the Treatment of Chronic Infectious Diseases
Research demonstrates Immuno-STAT™ Biologics lead to direct and selective activation and expansion of anti-viral cytotoxic T cells in vivo specific for human
About this update from Cue Biopharma, Inc.
[{"type":"text","content":"Research demonstrates Immuno-STAT™ Biologics lead to direct and selective activation and expansion of anti-viral cytotoxic T cells in vivo specific for human immunodeficiency virus (HIV) and cytomegalovirus (CMV) highlighting potential as immunotherapeutics for a variety of chronic infectious diseases\nCAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today the publication of a research study titled “T-Cell Receptor-specific Immunotherapeutics Drive Selective In vivo HIV and CMV- specific T-Cell Expansion in Humanized Mice” in the peer-reviewed Journal of Clinical Investigation. The article extends the application of Cue Biopharma’s Immuno-STAT (Selective Targeting and Alteration of T cells) platform, also known as synTacs™, from cancer therapy to the treatment of chronic infectious diseases caused by viruses such as HIV and CMV. The study was co-authored by Steven C. Almo, Ph.D., co-founder of Cue Biopharma, professor and chair of biochemistry, professor of physiology & biophysics and the Wollowick Family Foundation chair in multiple sclerosis and immunology at Albert Einstein College of Medicine, and Harris Goldstein, M.D., director of the Einstein-Rockefeller-CUNY Center for AIDS Research, professor of pediatrics and microbiology & immunology, the Charles Michael chair in autoimmune diseases and associate dean for scientific resources, also at Albert Einstein College of Medicine.“We hypothesized that we could boost the capacity of the natural immune response to effectively control and potentially clear chronic viral infections such as HIV and CMV by treating patients with biologics capable of selectively delivering the required primary and co-stimulatory signals needed to further activate and expand virus-specific immune T cells. Therapeutic approaches to date have not achieved this without ex vivo manipulation of immune T cells, which limits their clinical applicability,” said Dr. Goldstein. “We are pleased to demonstrate, using mice with a humanized immune system, the successful in vivo application of the Immuno-STAT framework, referred to as synTacs in the article, to selectively reactivate and expa...